Please assess the completion status of the following clinical trial:

Trial Title: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Triplication of glycine decarboxylase gene~Exclusion Criteria:~* Normal glycine decarboxylase copy number

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- glycine (Type: ACTIVE_COMPARATOR): Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
- Placebo (Type: PLACEBO_COMPARATOR): placebo, TID dosing, 6 weeks Double-blind
- glycine, open-label (Type: ACTIVE_COMPARATOR): glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).